- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03243708
Title: Randomized Trial of an EHR Embedded Risk Calculator vs. Standard VTE Prophylaxis for Medical Patients
Title: EHR Embedded Risk Calculator vs. Standard VTE Prophylaxis for Medical Patients
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Specific Aim:
Assess the effects of a VTE risk calculator embedded in the admission order set vs. usual care on physician behavior and patient outcomes in a randomized trial
Research Strategy:
Utilizing a Step-Wedge design, this randomized controlled trial (RCT) will be conducted at 10 Cleveland Clinic hospitals in efforts to assess the effects of a VTE (venous thromboembolism) risk calculator embedded in the admission order set vs. usual care on physician behavior and patient outcomes. Hospitals will be randomized to display the risk calculator to physicians admitting patients or to the usual order set that contains only a description of VTE risk factors. The risk calculator will produce a predicted risk of VTE together with a recommendation regarding the use of prophylaxis for an individual patient. Physicians will be free to ignore the calculator or override its results if they so choose.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Ohio
-
Cleveland, Ohio, United States, 44195
- Cleveland Clinic Health System
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- All adult patients (age ≥18 years) admitted to a medical service, including intensive care units, between September 1, 2017 and August 31, 2018 will be eligible.
Exclusion Criteria:
- patients not eligible to receive VTE prophylaxis because they are already receiving anticoagulation for another purpose (e.g. warfarin for atrial fibrillation or LMWH for DVT or PE present on admission),
- patients admitted with a terminal condition who are receiving comfort care only
- Surgical patients who are admitted to the medical service temporarily (e.g. hip fracture)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Usual Care
Control: Standard order set without risk calculator (usual care)
|
|
Active Comparator: Risk calculator
Intervention: VTE risk calculator embedded in the smart order set incorporated into the EHR and activated for all medical patients
|
Venous thromboembolism (VTE) risk calculator embedded in the admission order set with personalized recommendation for prophylaxis
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Appropriate VTE prophylaxis
Time Frame: within 48 hours of index hospitalization admission
|
Proportion of patients at high risk of VTE who receive prophylaxis and the proportion of patients at low risk who do not receive prophylaxis
|
within 48 hours of index hospitalization admission
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Total patients receiving prophylaxis
Time Frame: 14 days
|
All patients who received any chemoprophylaxis during hospitalization, regardless of risk status.
|
14 days
|
Rate of VTE among high risk patients
Time Frame: 14 days
|
Symptomatic VTE events not present on admission occurring among patients at high risk for VTE according to the risk calculator.
|
14 days
|
Rate of VTE among high risk patients
Time Frame: 45 days
|
Symptomatic VTE events not present on admission occurring among patients at high risk for VTE according to the risk calculator.
|
45 days
|
Rate of major bleeding among high risk patients
Time Frame: 14 days
|
Major bleeding events among patients with risk factors for bleeding.
|
14 days
|
Average cost of prophylaxis
Time Frame: 14 days
|
Total cost of prophylaxis received during hospitalization
|
14 days
|
Average cost of hospitalization
Time Frame: Up to 30 days
|
Cost of hospitalization as determined by the hospital cost accounting system
|
Up to 30 days
|
Average length of stay
Time Frame: Up to 30 days
|
Total days in hospital
|
Up to 30 days
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Michael Rothberg, The Cleveland Clinic
Publications and helpful links
General Publications
- Barbar S, Noventa F, Rossetto V, Ferrari A, Brandolin B, Perlati M, De Bon E, Tormene D, Pagnan A, Prandoni P. A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score. J Thromb Haemost. 2010 Nov;8(11):2450-7. doi: 10.1111/j.1538-7836.2010.04044.x.
- Lederle FA, Zylla D, MacDonald R, Wilt TJ. Venous thromboembolism prophylaxis in hospitalized medical patients and those with stroke: a background review for an American College of Physicians Clinical Practice Guideline. Ann Intern Med. 2011 Nov 1;155(9):602-15. doi: 10.7326/0003-4819-155-9-201111010-00008.
- Kakkar AK, Cimminiello C, Goldhaber SZ, Parakh R, Wang C, Bergmann JF; LIFENOX Investigators. Low-molecular-weight heparin and mortality in acutely ill medical patients. N Engl J Med. 2011 Dec 29;365(26):2463-72. doi: 10.1056/NEJMoa1111288.
- Rothberg MB, Lahti M, Pekow PS, Lindenauer PK. Venous thromboembolism prophylaxis among medical patients at US hospitals. J Gen Intern Med. 2010 Jun;25(6):489-94. doi: 10.1007/s11606-010-1296-y. Epub 2010 Mar 30.
- Cohen AT, Tapson VF, Bergmann JF, Goldhaber SZ, Kakkar AK, Deslandes B, Huang W, Zayaruzny M, Emery L, Anderson FA Jr; ENDORSE Investigators. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet. 2008 Feb 2;371(9610):387-94. doi: 10.1016/S0140-6736(08)60202-0. Erratum In: Lancet. 2008 Jun 7;371(9628):1914.
- Khanna R, Vittinghoff E, Maselli J, Auerbach A. Unintended consequences of a standard admission order set on venous thromboembolism prophylaxis and patient outcomes. J Gen Intern Med. 2012 Mar;27(3):318-24. doi: 10.1007/s11606-011-1871-x. Epub 2011 Sep 24.
- Qaseem A, Chou R, Humphrey LL, Starkey M, Shekelle P; Clinical Guidelines Committee of the American College of Physicians. Venous thromboembolism prophylaxis in hospitalized patients: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2011 Nov 1;155(9):625-32. doi: 10.7326/0003-4819-155-9-201111010-00011.
- Kucher N, Koo S, Quiroz R, Cooper JM, Paterno MD, Soukonnikov B, Goldhaber SZ. Electronic alerts to prevent venous thromboembolism among hospitalized patients. N Engl J Med. 2005 Mar 10;352(10):969-77. doi: 10.1056/NEJMoa041533.
- Dunn AS, Brenner A, Halm EA. The magnitude of an iatrogenic disorder: a systematic review of the incidence of venous thromboembolism for general medical inpatients. Thromb Haemost. 2006 May;95(5):758-62.
- Bhalla R, Berger MA, Reissman SH, Yongue BG, Adelman JS, Jacobs LG, Billett H, Sinnett MJ, Kalkut G. Improving hospital venous thromboembolism prophylaxis with electronic decision support. J Hosp Med. 2013 Mar;8(3):115-20. doi: 10.1002/jhm.1993. Epub 2012 Nov 26.
- Zeidan AM, Streiff MB, Lau BD, Ahmed SR, Kraus PS, Hobson DB, Carolan H, Lambrianidi C, Horn PB, Shermock KM, Tinoco G, Siddiqui S, Haut ER. Impact of a venous thromboembolism prophylaxis "smart order set": Improved compliance, fewer events. Am J Hematol. 2013 Jul;88(7):545-9. doi: 10.1002/ajh.23450. Epub 2013 Jun 12.
- Baio G, Copas A, Ambler G, Hargreaves J, Beard E, Omar RZ. Sample size calculation for a stepped wedge trial. Trials. 2015 Aug 17;16:354. doi: 10.1186/s13063-015-0840-9.
- Shekelle PG, Wachter RM, Pronovost PJ, Schoelles K, McDonald KM, Dy SM, Shojania K, Reston J, Berger Z, Johnsen B, Larkin JW, Lucas S, Martinez K, Motala A, Newberry SJ, Noble M, Pfoh E, Ranji SR, Rennke S, Schmidt E, Shanman R, Sullivan N, Sun F, Tipton K, Treadwell JR, Tsou A, Vaiana ME, Weaver SJ, Wilson R, Winters BD. Making health care safer II: an updated critical analysis of the evidence for patient safety practices. Evid Rep Technol Assess (Full Rep). 2013 Mar;(211):1-945.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 17-396
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Venous Thromboembolism
-
BayerWithdrawnTotal Hip Replacement | Total Knee Replacement | Prophylaxis, Thromboembolism, Venous
-
University Hospital, BrestRecruitingVenous Thromboembolism (VTE)France
-
University of ArizonaRecruitingPediatric Venous ThromboembolismUnited States
-
National Taiwan University HospitalUnknownDeep Venous ThromboembolismTaiwan
-
Ya-Wei XuFirst Affiliated Hospital, Sun Yat-Sen University; Nanfang Hospital of Southern...RecruitingVenous Thromboembolism (VTE)China
-
Bristol-Myers SquibbCompletedVenous Thromboembolism (VTE)United States
-
BayerCompletedTreatment of Venous ThromboembolismJapan
-
Azidus BrasilUnknownPrevention of Venous ThromboembolismBrazil
-
Fadoi Foundation, ItalyCompletedPrevention of Venous ThromboembolismItaly
-
Fadoi Foundation, ItalyUniversity Of PerugiaCompletedPrevention of Venous ThromboembolismItaly
Clinical Trials on Risk calculator
-
Duke UniversityWithdrawn
-
Medstar Health Research InstituteCompletedPelvic Organ Prolapse | Stress Urinary Incontinence | SatisfactionUnited States
-
Nepal Mediciti HospitalCompleted
-
prof. dr. Frans B. PlötzDutch Society of Pediatrics; Zorgevaluatie Nederland; Care4Neo; everywhereIMRecruitingEOS | Early-Onset Sepsis, NeonatalNetherlands
-
Fondazione del Piemonte per l'OncologiaSan Luigi Gonzaga Hospital; Epidemiology and Screening Unit - CPO, Turin, ItalyNot yet recruiting
-
Brigham and Women's HospitalCompletedKnee Osteoarthritis
-
Mehmet Ali KoçRecruitingComplication,Postoperative | Postoperative PeriodTurkey
-
Duke UniversityCompletedCardiovascular Disease | Diabetes | Ischemic Stroke | Peripheral Artery DiseaseUnited States
-
Mednax Center for Research, Education, Quality...Banner University Medical CenterCompletedMaternal; Chorioamnionitis, Affecting Fetus | Early-Onset Sepses, NeonatalUnited States
-
University of UtahCompletedDecision Support Systems, Clinical | Algorithms | Diarrhea Infectious | Clinical Decision-MakingBangladesh, Mali